PaperPaper Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma External Link Read MorePaper A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer External Link Read MorePaper Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. External Link Read MorePaper A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia PDF (1.15 MB) Read MorePaper Promising Activity Of Selinexor In The Treatment Of A Patient With Refractory Diffuse Large B-Cell Lymphoma And Central Nervous System Involvement External Link Read MorePaper Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom’s macroglobulinemia External Link Read MorePaper Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis External Link Read MorePaper Selective Inhibition of Nuclear Export with Selinexor in Patients with Non-Hodgkin’s Lymphoma External Link Read MorePaper A Phase I Clinical Trial of Single-Agent Selinexor in Acute Myeloid Leukemia External Link Read MorePaper Selective inhibitor of nuclear export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3 PDF (19.01 MB) Read More1 2 3 … 7 Next